Immunoglobulin E specific to Cynodon dactylon pollen allergens (Cyn d-specific IgE)

Immunoglobulin E (IgE) antibodies specific to Cynodon dactylon (Bermuda grass) pollen allergens are the primary mediators of Type I hypersensitivity in sensitized individuals (Source: World Allergy Organization). These antibodies are produced by B cells and circulate in the blood before binding to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils. When an individual is re-exposed to Bermuda grass pollen, allergens such as the major allergen Cyn d 1 cross-link the receptor-bound IgE molecules (Source: WHO/IUIS Allergen Nomenclature). This cross-linking triggers an intracellular signaling cascade leading to the degranulation of mast cells and the release of inflammatory mediators like histamine and leukotrienes (Source: PubMed, PMID: 12847331). These mediators are responsible for the clinical manifestations of allergic rhinitis, conjunctivitis, and allergic asthma. Therapeutic targeting of these specific IgE antibodies is achieved through monoclonal antibodies like omalizumab, which sequester free IgE and prevent its binding to FcεRI. Furthermore, allergen-specific immunotherapy (AIT) utilizes Cynodon dactylon extracts to desensitize the immune system, promoting a shift from IgE production to protective IgG4 production (Source: NIH/NIAID).

Other names

Bermuda grass-specific IgEAnti-Cynodon dactylon IgECyn d 1-specific IgECyn d-specific IgE

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils, which leads to a downregulation of these receptors and a reduction in mediator release (Source: PubMed, PMID: 12847331). Allergen-specific immunotherapy (AIT) involves the administration of Cynodon dactylon extracts to induce peripheral T-cell tolerance and promote the production of allergen-specific IgG4 antibodies that compete with IgE for allergen binding (Source: NIH/NIAID).